Oxford–AstraZeneca COVID-19 vaccine
Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca
Oxford–AstraZeneca COVID-19 vaccine ▸ Facts ▸ Comments ▸ News ▸ Videos
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.
| 0 shares | ShareTweetSavePostSend |
You Might Like
1 in 3 Covaxin recipients hit by adverse events: StudyNearly one-third of Covaxin recipients experienced adverse events of special interest within a year, including respiratory, skin, and musculoskeletal issues. The study also highlighted menstrual..IndiaTimes - Published | |
Stopped producing Covishield in Dec 2021: SII after AstraZeneca recallUK-based drug major AstraZeneca's decision to withdraw its Covid-19 vaccine globally, days after admitting to side effects, prompted Serum Institute of India to disclose that it had stopped..IndiaTimes - Published | |
'Manufacturing of Covishield ceased two years back due to poor demand'IndiaTimes - Published | |
SII stopped manufacturing Covishield since December 2021, says 'disclosed side effects details in packaging insert'SII stopped Covishield extra doses due to lawsuit, disclosed rare Thrombosis. Advocates govt collaboration. AstraZeneca withdraws Vaxzevria marketing authorisations globally. European Medicines Agency..IndiaTimes - Published | |
55% Covidshield recipients had mild side effects: AMCH studyIndiaTimes - Published | |
AstraZeneca admits Covishield vaccines raises rare side-effects risk. How worried should you be?In India, almost 90% of people who received Covid vaccine, received the AstraZeneca vaccine which in India is called Covishield.DNA - Published | |
Take down defamatory posts on Covishield: Bombay high courtIndiaTimes - Published | |
Content posted against Serum Institute of India, its Covishield vaccine prima facie defamatory: Bombay HCThe Bombay high court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and..IndiaTimes - Published | |
SII to restart vaccine production amid surge in Covid casesSerum Institute of India CEO Adar Poonawalla told TOI on Wednesday that the company has resumed production of its Covid-19 vaccine, Covishield, in response to the increasing number of SARS-CoV-2 virus..IndiaTimes - Published | |
Serum Institute of India restarts manufacturing of Covid-19 vaccine CovishieldSerum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection. He said the..IndiaTimes - Published | |
Covid jab Covovax as heterologous booster to be available on CoWIN soon; to cost Rs 225 per doseCovovax can be administered to those who have already vaccinated with Covishield or Covaxin. The Drugs Controller General of India (DCGI) on January 16 had approved the market authorisation for Covovax..IndiaTimes - Published | |
Drug panel favours nod for Covovax as Covid boosterAn expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India’s Covid vaccine, Covovax, as a heterologous booster dose for adults who have..IndiaTimes - Published | |
Covovax may get approval as heterologous boosterThe government may decide on allowing Serum Institute of India’s (SII) Covovax as a heterologous booster dose, meaning it can be used for people who have taken either Covishield or Covaxin for..IndiaTimes - Published | Covid-19: Covovax to get approval as booster in 10-15 days, says SII CEO Adar PoonawallaSerum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works very well against the..IndiaTimes - Published |
